ERF (ETS2 repressor factor) is a transcriptional repressor that negatively regulates RAS-MAPK signaling through sequence-specific DNA binding 1. As a member of the AP2/ERF transcription factor family 2, ERF functions as a potent repressor involved in developmental processes including trophoblast differentiation and potentially skeletal development. Loss-of-function variants in ERF cause a RASopathy phenotype resembling Noonan syndrome, characterized by developmental delay, distinctive facial features (macrocephaly, hypertelorism, ptosis), and growth deficiency, with craniosynostosis occurring in approximately 12% of affected individuals 1. ERF haploinsufficiency through truncating and frameshift mutations leads to dysregulation of MAPK signaling 1. In systemic sclerosis, ERF overexpression in endothelial cells is associated with dysregulated angiogenesis and arterial endothelial apoptosis 3. Clinical manifestations of ERF-related disorders include cognitive difficulties (attention deficits, fine motor impairment), high-frequency speech and language difficulties, and otologic complications 4. Established ERF knockout human embryonic stem cell lines maintain pluripotency while enabling investigation of ERF's roles in development and differentiation 5. These findings establish ERF as a critical negative regulator of proliferative signaling with broad implications for developmental and vascular biology.